A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells. Leuk Res 2010 Jul;34(7):950-3
Date
03/26/2010Pubmed ID
20334913Pubmed Central ID
PMC2875307DOI
10.1016/j.leukres.2010.02.034Scopus ID
2-s2.0-77952958393 (requires institutional sign-in at Scopus site) 20 CitationsAbstract
Combination chemotherapy forms the backbone of cancer treatment. There is a need for new drug combinations for the treatment of mantle cell lymphoma (MCL). Herein, we show that gallium maltolate, a novel gallium compound, synergizes with bortezomib, a proteasome inhibitor, to induce cell death in MCL Granta cells. Cells exposed to either agent displayed caspase-3 activation, a loss of mitochondrial membrane potential, and a decrease in chymotrypsin-like activity. These effects were increased with both agents in combination. Our results show for the first time that the proteasome may be a target for gallium maltolate and suggest that the therapeutic potential of combination bortezomib and gallium maltolate warrants further investigation.
Author List
Chitambar CR, Purpi DPMESH terms used to index this publication - Major topics in bold
ApoptosisBoronic Acids
Bortezomib
Caspase 3
Cell Division
Cell Line, Tumor
Chymotrypsin
Drug Screening Assays, Antitumor
Drug Synergism
Enzyme Activation
Humans
Lymphoma, Mantle-Cell
Membrane Potential, Mitochondrial
Neoplasm Proteins
Organometallic Compounds
Protease Inhibitors
Proteasome Inhibitors
Pyrazines
Pyrones
